Home  »  Trending   »  Looking Closely at the Growth Curve for Emergent B...

Looking Closely at the Growth Curve for Emergent BioSolutions Inc. (EBS)

Emergent BioSolutions Inc. (NYSE:EBS) went down by -11.60% from its latest closing price compared to the recent 1-year high of $66.78. The company’s stock price has collected -12.01% of loss in the last five trading sessions. The Wall Street Journal reported on 06/06/22 that J&J Plans to End Covid-19 Vaccine Deal With Emergent BioSolutions

Is It Worth Investing in Emergent BioSolutions Inc. (NYSE :EBS) Right Now?

Emergent BioSolutions Inc. (NYSE:EBS) scored a price-to-earnings ratio above its average ratio, recording 10.29 x from its present earnings ratio. Plus, the 36-month beta value for EBS is at 1.00.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $43.29, which is $14.07 above the current price. EBS currently public float of 45.17M and currently shorts hold a 7.62% ratio of that float. Today, the average trading volume of EBS was 744.69K shares.

EBS’s Market Performance

EBS stocks went down by -12.01% for the week, with a monthly drop of -4.93% and a quarterly performance of -10.42%, while its annual performance rate touched -52.51%. The volatility ratio for the week stands at 8.41% while the volatility levels for the past 30 days are set at 5.53% for Emergent BioSolutions Inc. The simple moving average for the period of the last 20 days is -7.23% for EBS stocks with a simple moving average of -23.94% for the last 200 days.

Analysts’ Opinion of EBS

The Benchmark Company, on the other hand, stated in their research note that they expect to see EBS reach a price target of $77. The rating they have provided for EBS stocks is “Buy” according to the report published on January 20th, 2022.

EBS Trading at -5.40% from the 50-Day Moving Average

After a stumble in the market that brought EBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.69% of loss for the given period.

Volatility was left at 5.53%, however, over the last 30 days, the volatility rate increased by 8.41%, as shares sank -9.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.51% lower at present.

During the last 5 trading sessions, EBS fell by -12.01%, which changed the moving average for the period of 200-days by -41.19% in comparison to the 20-day moving average, which settled at $32.47. In addition, Emergent BioSolutions Inc. saw -30.39% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at EBS starting from Zoon Kathryn C, who sale 1,173 shares at the price of $31.52 back on Jun 09. After this action, Zoon Kathryn C now owns 19,654 shares of Emergent BioSolutions Inc., valued at $36,973 using the latest closing price.

Zoon Kathryn C, the Director of Emergent BioSolutions Inc., sale 1,996 shares at $35.53 during a trade that took place back on May 24, which means that Zoon Kathryn C is holding 12,381 shares at $70,918 based on the most recent closing price.

Stock Fundamentals for EBS

Current profitability levels for the company are sitting at:

  • +22.21 for the present operating margin
  • +54.64 for the gross margin

The net margin for Emergent BioSolutions Inc. stands at +12.88. Equity return is now at value 10.10, with 5.50 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 3.40.